Assets, trials, companies, and catalysts—linked to the record.
A structured intelligence layer for peptide therapeutics from discovery through approval, discontinuation, licensing, and acquisition.
Pipeline snapshot
View all →Tracked assets
15
Active clinical / approved
15
Modalities
4
Verified catalysts
6
Upcoming catalysts
View all →retatrutide-triumph-readout
Phase 3 TRIUMPH readouts expected 2026-2027.
window · Jan 1, 2026
tirzepatide-surmount-mmo-topline
Topline data from SURMOUNT-MMOE cardiovascular outcomes trial expected 2025.
window · Jan 1, 2025
cagrisema-redefine-1-readout
REDEFINE 1 topline readout anticipated in 2025.
window · Jan 1, 2025
danuglipron-phase-3-start
Pfizer expects to advance danuglipron once-daily formulation into phase 3 in 2025.
window · Jan 1, 2025
gsbr-1290-phase-2-readout
Phase 2 obesity readout expected second half of 2024.
window · Sep 1, 2024
semaglutide-select-mace-label-expansion
FDA action on MACE risk reduction indication based on SELECT trial.
window · Jan 1, 2024
Latest readouts
View all →Retatrutide phase 2 shows up to 24.2% mean weight loss at 48 weeks
Clinical trial registry and conference presentation
Jun 26, 2023
AMG 133 phase 1 demonstrates up to 14.5% weight loss after 12 weeks
ClinicalTrials.gov record and conference abstract
Dec 8, 2022
Tirzepatide SURPASS-2 delivers superior HbA1c and weight reductions vs semaglutide 1 mg
Clinical trial registry and NEJM publication
Aug 5, 2021
Semaglutide 2.4 mg achieves 14.9% mean weight loss in STEP 1
Clinical trial registry and NEJM publication
Mar 18, 2021
Notable deals
View all →roche-acquires-carmot-therapeutics
Roche Holding AG and Carmot Therapeutics Inc. · acquisition
Headline: $3.1 billion (contingent)
lilly-orforglipron-collaboration
Eli Lilly and Company and Chugai Pharmaceutical Co., Ltd. · licensing
Headline: Not disclosed (contingent)
boehringer-zealand-survodutide-partnership
Boehringer Ingelheim International GmbH and Zealand Pharma A/S · partnership
Headline: Up to $500 million (contingent)
novo-nordisk-emisphere-oral-semaglutide
Novo Nordisk A/S and Emisphere Technologies Inc. · licensing
Headline: Up to $105 million (contingent)
Featured landscape: Obesity
View all →Tirzepatide
Once-weekly dual GIP and GLP-1 receptor agonist that improves glycemic control and drives weight loss.
Semaglutide
Long-acting GLP-1 receptor agonist with amino-acid substitutions and fatty-acid side chain for albumin binding.
Retatrutide
Once-weekly triple agonist of GLP-1, GIP, and glucagon receptors in development for obesity and related conditions.
Cagrisema
Fixed-dose combination of long-acting amylin analogue cagrilintide and semaglutide for enhanced weight loss.
Mazdutide
OXM-derived dual GLP-1 and glucagon receptor agonist licensed from Eli Lilly and developed in China.
Danuglipron
Oral small-molecule GLP-1 receptor agonist being evaluated in twice-daily and once-daily formulations.
Data methodology
Every material assertion is tied to a controlling source. We prefer registry records, peer-reviewed papers, regulatory labels, and SEC filings over press-release interpretation.
Read the methodologyPipeline Brief
One concise weekly view of stage changes, readouts, catalysts, and deals—each with direct source links.
Latest reports
View all →GLP-1 and Incretin Landscape: From Ozempic to Triple Agonists
A strategic overview of approved and pipeline incretin-based peptide therapeutics.
Aug 15, 2024
Oral GLP-1 Competitive Assessment: Pills vs Injections
Evaluating oral peptide and small-molecule approaches in the GLP-1 class.
Aug 12, 2024
Obesity Market Outlook: Supply, Pricing, and Next-Generation Assets
Commercial dynamics shaping the obesity therapeutic market through 2030.
Aug 10, 2024